Total Payments
$141,922
2024 Payments
$55,767
Companies
11
Transactions
257
Medicare Patients
1,507
Medicare Billing
$157,322
Payment Breakdown by Category
Consulting$115,981 (81.7%)
Food & Beverage$12,131 (8.5%)
Travel$10,080 (7.1%)
Research$3,673 (2.6%)
Education$55.98 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $115,981 | 27 | 81.7% |
| Food and Beverage | $12,131 | 163 | 8.5% |
| Travel and Lodging | $10,080 | 52 | 7.1% |
| Unspecified | $3,673 | 12 | 2.6% |
| Education | $55.98 | 3 | 0.0% |
Payments by Type
General
$138,248
245 transactions
Research
$3,673
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $67,377 | 126 | $0 (2024) |
| Insmed, Inc. | $34,889 | 10 | $0 (2024) |
| Merck Sharp & Dohme LLC | $15,719 | 23 | $0 (2024) |
| United Therapeutics Corporation | $11,921 | 66 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $8,524 | 6 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $2,025 | 2 | $0 (2021) |
| Gilead Sciences, Inc. | $881.45 | 14 | $0 (2018) |
| Actelion Pharmaceuticals, Ltd | $479.41 | 6 | $0 (2019) |
| Sandoz Inc. | $74.14 | 2 | $0 (2024) |
| Philips North America LLC | $19.21 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $55,767 | 38 | Insmed, Inc. ($28,005) |
| 2023 | $30,705 | 49 | Actelion Pharmaceuticals US, Inc. ($7,748) |
| 2022 | $8,459 | 27 | Actelion Pharmaceuticals US, Inc. ($3,185) |
| 2021 | $3,042 | 15 | Bayer HealthCare Pharmaceuticals Inc. ($1,900) |
| 2020 | $2,838 | 4 | United Therapeutics Corporation ($2,838) |
| 2019 | $1,395 | 13 | United Therapeutics Corporation ($880.59) |
| 2018 | $4,881 | 36 | Actelion Pharmaceuticals US, Inc. ($2,243) |
| 2017 | $34,834 | 75 | Actelion Pharmaceuticals US, Inc. ($33,596) |
All Payment Transactions
257 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $143.35 | General |
| Category: Cardiology | ||||||
| 12/05/2024 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $54.51 | General |
| 11/01/2024 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,060.00 | General |
| 10/23/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $5,490.00 | General |
| 10/23/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 10/22/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $149.00 | General |
| 10/17/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $352.95 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/16/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $388.43 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/26/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $137.20 | General |
| 08/15/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $113.41 | General |
| 06/29/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $115.23 | General |
| 06/28/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $81.45 | General |
| Category: Cardiology | ||||||
| 06/28/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $47.10 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 05/21/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| Category: Cardiology | ||||||
| 05/21/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 05/21/2024 | United Therapeutics Corporation | TYVASO (Drug), REMODULIN | Food and Beverage | In-kind items and services | $46.71 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 05/18/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Consulting Fee | Cash or cash equivalent | $6,075.00 | General |
| Category: Cardiology | ||||||
| 05/18/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: Cardiology | ||||||
| 05/18/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Cardiology | ||||||
| 05/17/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Travel and Lodging | In-kind items and services | $382.15 | General |
| Category: Cardiology | ||||||
| 05/09/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Travel and Lodging | Cash or cash equivalent | $94.43 | General |
| Category: Cardiology | ||||||
| 05/09/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Travel and Lodging | Cash or cash equivalent | $48.00 | General |
| Category: Cardiology | ||||||
| 05/09/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | Cash or cash equivalent | $41.68 | General |
| Category: Cardiology | ||||||
| 05/08/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Travel and Lodging | In-kind items and services | $342.03 | General |
| Category: Cardiology | ||||||
| 05/08/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Cardiology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION PH IN HEART FAILURE WITH PRESERVED EJECTION FRACTION HFPEF | United Therapeutics Corporation | $2,289 | 7 |
| An Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | Insmed, Inc. | $1,384 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 541 | 577 | $265,516 | $43,465 |
| 2022 | 6 | 346 | 409 | $197,270 | $41,132 |
| 2021 | 5 | 375 | 475 | $64,501 | $46,469 |
| 2020 | 5 | 245 | 279 | $40,210 | $26,256 |
Total Patients
1,507
Total Services
1,740
Medicare Billing
$157,322
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 63 | 75 | $45,300 | $9,806 | 21.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 85 | 99 | $44,550 | $8,938 | 20.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 40 | 40 | $35,640 | $6,683 | 18.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 35 | 35 | $24,745 | $4,458 | 18.0% |
| 94621 | Test for exercise-induced heart and lung stress | Office | 2023 | 29 | 33 | $33,759 | $3,664 | 10.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 71 | 71 | $22,081 | $3,108 | 14.1% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 67 | 67 | $21,239 | $2,829 | 13.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 19 | $5,624 | $1,295 | 23.0% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 42 | 42 | $14,364 | $1,261 | 8.8% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 51 | 55 | $11,395 | $1,082 | 9.5% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 25 | 26 | $5,454 | $235.59 | 4.3% |
| 94640 | Inhalation treatment for airway obstruction or sputum production | Office | 2023 | 14 | 15 | $1,365 | $105.60 | 7.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 97 | 121 | $73,084 | $16,871 | 23.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 42 | 42 | $37,422 | $7,508 | 20.1% |
| 94621 | Test for exercise-induced heart and lung stress | Office | 2022 | 62 | 68 | $50,028 | $7,378 | 14.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 59 | 62 | $27,900 | $6,026 | 21.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 73 | 102 | $4,692 | $2,310 | 49.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 14 | $4,144 | $1,040 | 25.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 99 | 132 | $26,064 | $18,718 | 71.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 61 | 61 | $13,633 | $10,775 | 79.0% |
| 94621 | Test for exercise-induced heart and lung stress | Office | 2021 | 70 | 83 | $15,456 | $9,224 | 59.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 43 | 45 | $5,837 | $4,351 | 74.5% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 102 | 154 | $3,511 | $3,400 | 96.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 76 | 90 | $14,509 | $9,334 | 64.3% |
| 94621 | Test for exercise-induced heart and lung stress | Office | 2020 | 59 | 68 | $12,373 | $7,284 | 58.9% |
About Dr. Charles Burger, MD
Dr. Charles Burger, MD is a Pulmonary Disease healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/05/2005. The National Provider Identifier (NPI) number assigned to this provider is 1790772671.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Burger, MD has received a total of $141,922 in payments from pharmaceutical and medical device companies, with $55,767 received in 2024. These payments were reported across 257 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($115,981).
As a Medicare-enrolled provider, Burger has provided services to 1,507 Medicare beneficiaries, totaling 1,740 services with total Medicare billing of $157,322. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Jacksonville, FL
- Active Since 10/05/2005
- Last Updated 08/31/2020
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1790772671
Products in Payments
- OPSUMIT (Drug) $20,030
- UPTRAVI (Drug) $19,286
- ORENITRAM (Drug) $5,705
- Adempas (Drug) $2,025
- OPSUMIT MACITENTAN (Drug) $1,032
- WINREVAIR (Biological) $759.47
- TYVASO (Drug) $622.59
- REMODULIN (Drug) $244.05
- TREPROSTINIL (Drug) $74.14
- Letairis (Drug) $49.62
- (7029) PIC IX Data Management (Device) $19.21
- CFN Pyxis (Device) $12.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Jacksonville
Dr. Abubakr Bajwa, M.d, M.D
Pulmonary Disease — Payments: $586,209
Pulmonary Disease $586,209
Jorge Mallea, Md, MD
Pulmonary Disease — Payments: $206,363
Pulmonary Disease $206,363
Dr. Sebastian Fernandez-Bussy, M.d, M.D
Pulmonary Disease — Payments: $125,148
Pulmonary Disease $125,148
Dr. Daniel Wyzan, Md, MD
Pulmonary Disease — Payments: $113,878
Pulmonary Disease $113,878
Peter Nassar, Md, MD
Pulmonary Disease — Payments: $80,367
Pulmonary Disease $80,367
Mitchell Rothstein, Md, MD
Pulmonary Disease — Payments: $64,712
Pulmonary Disease $64,712